Programmable Immune Reactive Cell therapy

Programmable Immune Reactive Cell therapy (PIRCs) is a first-in-class adoptive cell therapy designed to treat solid tumors by leveraging plasmacytoid dendritic cell (pDC)-like properties. These autologous cells are generated from hematopoietic stem and progenitor cells (HSPCs) and genetically engineered using a SyNthetic Intramembrane Proteolysis Receptor (SNIPR) system. This engineering prompts an antigen-dependent immune response through the stimulation of a STING gain-of-function gene (STINGv155M). PIRCs are designed for precision activation towards specific tumor antigens, leading to direct killing of cancer cells, recruitment of immune cells, elevated NK cell cytotoxic functions, and the induction of a rapid and broad immune response, including type I interferon (IFNα) and chemokines. The therapy aims to overcome the immunosuppressive tumor microenvironment.